Abstract 243: A Novel Cost Effectiveness Model of Eicosapentaenoic Acid (EPA) for Secondary Prevention in the United States [Session Title: Poster Session II]

Conclusions: This novel model suggests that combining EPA with statin therapy for secondary prevention of cardiovascular disease in the United States may be cost-saving and appears to be a more compelling intervention than statin monotherapy. The framework of this model provides a starting point for development of microsimulation models as more data become available.

Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Schmier, J. K., Hulme-Lowe, C., Nelson, J. R., Chowdhury, S., Everett, P. B., Philip, S. Tags: Session Title: Poster Session II Source Type: research